Navigation Links
Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
Date:2/1/2012

SAN DIEGO, and WOODCLIFF LAKE, N.J., Feb. 1, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified Arena that an Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss the lorcaserin New Drug Application (NDA) resubmission will be held in the second quarter of 2012. Confirmation and details of the meeting will be published in the Federal Register.

Lorcaserin is an investigational drug candidate intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition. Arena resubmitted the lorcaserin NDA in December 2011, and the FDA assigned a new Prescription Drug User Fee Act (PDUFA) target date of June 27, 2012.

About LorcaserinLorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the lorcaserin NDA.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic are
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" report ... was approved by CFDA to treat wet age- related ... product of Novartis, is available in the Chinese market. ... drug for the treatment of wet AMD in ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... and PITTSBURGH , Aug. 28, ... today announced that its shareholders have approved Mylan,s ... PRGO ; TASE) and the related issuance of ... extraordinary general meeting of shareholders held today. The ... at the extraordinary general meeting. In addition, the ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... Inc. (DCI), announced that the company has received ... its New Drug Application (NDA) for PERTZYE™, indicated ... due to cystic fibrosis (CF) or other conditions.  ... enzyme product containing bicarbonate-buffered enteric-coated microspheres and is ...
... Inc. today announced that company personnel will deliver a ... Week (DDW) annual meeting at 9 a.m. PDT on ... Center in San Diego, California. DDW attracts thousands of ... share the latest research in gastrointestinal health topics, for ...
Cached Medicine Technology:Digestive Care, Inc. Announces FDA Approval of PERTZYE™ (pancrelipase) Delayed-Release Capsules 2Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease 2
(Date:8/31/2015)... ... 31, 2015 , ... Intellitec Solutions announced they have reached a record for ... new staff member in 2015. With the potential for more hiring occurring before the ... Dynamics GP, Dynamics SL, Dynamics CRM and Intacct, and has hired new support staff ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in business ... marketing a doctor note service to be made available to all patients and ... each generated excuse, much less than the average daily pay of workers. ...
(Date:8/30/2015)... California (PRWEB) , ... August 31, 2015 , ... Avid ... Morrison and the Doors Shrine Auditorium concert posters. This hand colored artwork is one ... and 23 in Los Angles. Hawley states, "When the doors played the Shrine, ...
(Date:8/30/2015)... ... 2015 , ... ChopChop Kids, the nonprofit publisher of the ... two new officers to serve on the organization’s Board of Directors in accordance ... kids to cook real food with their families and help continue to drive ...
(Date:8/30/2015)... ... ... Scientists in France say asbestos exposure may put workers at higher risk ... just posted an article on the new research. Click here to read it ... 2,024 French asbestos plant workers from 1978 to 2009. In addition to mesothelioma, the ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2
... in as the 5th Chair on "The Doctors", LOS ... be the guest co-host on the number one new syndicated,talk ... (check local,listings, http://www.thedoctorstv.com )., Best known from the ... York Times Bestselling Author for his book, Billion Dollar Smile,sits ...
... fatal parasite; first vaccines delivered following major funding award. ... that could eradicate a fatal form of brain disease ... soon be commercially available thanks to multi-million dollar funding. ... million tapeworm infections and 50,000 deaths from brain disease ...
... Abbott (NYSE: ABT ),will present at the 17th ... Thomas C. Freyman, executive vice president, finance,and chief financial ... 5,p.m. CST., A live audio webcast of the ... at http://www.abbottinvestor.com . An,archived edition of the presentation ...
... for stroke ... treatment, ... a team,of stroke experts from the West Virginia University Health Sciences ... The study showed CT perfusion had,100 percent accuracy for detecting the ...
... of America, Inc.,(OTC Bulletin Board: CPCF), a company ... in endovascular procedures, today announced,that it is implementing ... its MedClose(TM) investigational-stage medical device. In,the roll out ... Medical,Product Service GmbH (MPS) of Germany to act ...
... Emergency Room Life Through Eyes of Poet Doctor, ... care,crisis in America to the natural fear of illness ... wonder and poetry in medical practice.,Bertrand P. Fote has ... his,work as an emergency physician, and he captures this ...
Cached Medicine News:Health News:Celebrity Cosmetic Dentist to Guest Co-Host New National Day Time Talk Show 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 3Health News:West VA University Study Calls for New Method of Stroke Diagnosis 2Health News:West VA University Study Calls for New Method of Stroke Diagnosis 3Health News:West VA University Study Calls for New Method of Stroke Diagnosis 4Health News:CPC Appoints Medical Product Service GmbH as Authorized European Representative for MedClose(TM) System 2Health News:CPC Appoints Medical Product Service GmbH as Authorized European Representative for MedClose(TM) System 3Health News:Physician Portrays Powerful Poetry at Heart of Human Condition 2
... Designed with patient need and ... Orthotic Appliance) family of products effectively ... indications. The Chairback frame attachment provides ... orthosis (LSO) provides superior support for ...
Effectively stabilize and relax your back with the LumboTrain back support....
... to superior immobilization and cervical spine care, one ... already know that the most important function of ... But what you may not know is that ... provides superior immobilization over the leading one-piece rigid ...
Distinct male and female designs for proper anatomical fit. Hip and pelvic components sized independently. Rigid posterior tongue minimizes pelvic rotation. Available in black or white plastic. Aggre...
Medicine Products: